High secondary resistance to quinolones in German Helicobacter pylori clinical isolates

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 7, 2013, Pages 1562-1566

  Wueppenhorst, Nicole ^a   Stueger, Hans Peter ^b   Kist, Manfred ^a   Glocker, Erik Oliver ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

Author keywords

GyrA; Mutations; Surveillance

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; CIPROFLOXACIN PLUS LEVOFLOXACIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; QUINOLONE; RIFAMPICIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM ISOLATE; CONTROLLED STUDY; GERMANY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; RISK FACTOR; STOMACH;

EID: 84879544629     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt061     Document Type: Article

References (17)

1. Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline 'Helicobacter pylori and gastroduodenal ulcer disease' of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e. V., German Society for Rheumatology, AWMF-Registration-no. 021/001. Z Gastroenterol 2009; 47: 1230-63.
2. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009; 136: 1863-73.
3. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
4. Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
5. McNulty CA, Lasseter G, Shaw I et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 2012; 35: 1221-30.
6. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007; 51: 346-9.
7. Bogaerts P, Berhin C, Nizet H et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006; 11: 441-5.
8. Kist M. Diagnostische Verfahrensrichtlinien der DGHM: Isolierung und Identifizierung von Bakterien der Gattungen Campylobacter und Helicobacter. Zentralbl Bakteriol 1991; 276: 124-39.
9. Glocker E, Bogdan C, Kist M. Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany. J Antimicrob Chemother 2007; 59: 874-9.
10. Wueppenhorst N, Stueger HP, Kist M et al. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother 2009; 63: 648-53.
11. Miendje Deyi VY, Burette A, Bentatou Z et al. Practical use of GenoTypew HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing. Diagn Microbiol Infect Dis 2011; 70: 557-60.
12. Cambau E, Allerheiligen V, Coulon C et al. Evaluation of a new test, GenoType HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009; 47: 3600-7.
13. Wüppenhorst N, Lenze F, Ross M et al. Isolation and eradication of a clinical isolate of Helicobacter pylori resistant to five antimicrobials in Germany. J Antimicrob Chemother 2011; 66: 222-3.
14. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322.
15. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84.
16. Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-13.
17. Laine L, Hunt R, El-Zimaity H et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-7.